Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

H Gogas,B Dréno,J Larkin,L Demidov,D Stroyakovskiy,Z Eroglu,P Francesco Ferrucci,J Pigozzo,P Rutkowski,J Mackiewicz,I Rooney,A Voulgari,S Troutman, B Pitcher,Y Guo,Y Yan,M Castro,S Mulla,K Flaherty,A Arance

Annals of Oncology（2021）

Cited 65|Views90

No score

Abstract

•Cobimetinib plus atezolizumab did not improve PFS versus pembrolizumab monotherapy in BRAFV600 wild-type advanced melanoma.•Results were consistent across prespecified subgroups according to known prognostic factors.•Higher tumor mutational burden was associated with improved clinical outcomes in both treatment arms.•As expected, the combination was associated with a higher incidence of AEs than pembrolizumab monotherapy.

Translated text

Key words

atezolizumab,cobimetinib,pembrolizumab,melanoma,BRAF wild-type

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined